Here is the latest on the IBD 50 stocks investing strategies vs. $SPY
VRX led the IBD 50, up 8.32% for the week. The biggest loser for the IBD 50 was VIPS, down 7.32%.
The IBD 50 portfolios total return since 2/8/2014 are underperforming the SP500. None of the strategies are beating the simple SP500 at this point. I would have expected to see the leading stocks lead, but there has been more volatility in some of the top stocks as measured by IBD.
The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50. Dividends are excluded from total returns.
Trading costs $805.95.
All of the portfolios have a positive return for the month, but have a positive total return.
The IBD 50 has 28 gainers and 22 losers in November.
AFSI is the top performer for the IBD 50, returning 13.91%. The weakest stock in the IBD 50 so far is SLXP, losing 28.47%.
Trading costs $169.15
I will assume a $9.95 trading cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio. (Imagine the costs of doing this with individual stocks, compared to using Motif. Note that Motif limits the size of portfolios to 30 stocks).
The Top 25 holdings are listed at at Motif Investing. (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).
None of the above strategies are a recommendation to buy or sell stocks. These are model portfolios constructed for entertainment only.
This is the IBD portfolio performance since 2/8/2014. Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model. Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month. It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio. Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90. Daily changes in the IBD 50 or stock rankings are not considered. Changes in IBD’s overall market views are not considered. Stop loss orders or other market timing strategies are not considered. The value for SPY is based on buying 2/8/2014.
Based on a blog entry from Paladin Money. See Investors Business Daily for more information on the IBD 50. See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.